Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share
Seres Therapeutics made money this quarter instead of losing it, and earned way more than experts thought it would. When a company surprises everyone by doing much better than expected, that's a sign things might be going well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.